<DOC>
	<DOCNO>NCT01126645</DOCNO>
	<brief_summary>The purpose study evaluate Sorafenib local microtherapy guide Primovist enhance MRI patient inoperable liver cancer ( HCC ) . Methodology : Patients diagnosis hepatocellular carcinoma receive either : - local ablation therapy liver lesion radiofrequency ablation follow sorafenib placebo ( local ablation group ) , - radioembolization ( SIRT ) + sorafenib sorafenib alone ( palliative treatment group ) . In study group , patient randomize one two treatment arm follow pre-defined randomization plan . Randomization 1:1 basis local ablation group basis 10 ( sorafenib ) : 11 ( SIRT + sorafenib ) palliative treatment group . Patients local ablation group follow 2 month interval recurrence overall survival , patient palliative treatment group follow overall survival . Follow-up study group end 24 month inclusion last patient respective study group . The assignment patient local ablation palliative study group base ablative potential RFA ( local ablation ≤4 tumor , ≤5 cm size ) . Diagnostic imaging use guide decision . The assignment local ablation palliative treatment group make local investigator . As sub-study , patient undergo Primovist®-enhanced MRI addition contrast-enhanced CT assignment one treatment group . The goal sub-study assess value Primovist®-enhanced MRI correctly stratify patient local ablation palliative treatment strategy . Primovist®-enhanced MRI compare contrast-enhanced multislice CT use truth panel assessment standard reference . In addition , Primovist-enhanced MRI contrast-enhanced CT obtain follow-up patient local ablation group assess potential detection recurrence .</brief_summary>
	<brief_title>Sorafenib Micro-therapy Guided Primovist Enhanced MRI Patients With Inoperable Liver Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Inclusion Criteria 1 . Age : 1885 year 2 . Diagnosis hepatocellular carcinoma 3 . If primary diagnosis HCC : diagnosis base follow criterion : 1. cytohistological criterion , OR 2. radiological criterion : Focal lesion &gt; 1 cm arterial hypervascularization 2 coincident image technique ( CT , MRI , US ) , OR 3. combine criterion : one imaging technique show focal lesion 12 cm arterial hypervascularization AND AFP level &gt; 400 ng/mL , OR 4. combine criterion : one imaging technique show focal lesion &gt; 2 cm arterial hypervascularization AND AFP level &gt; 200 ng/mL 4 . If extrahepatic metastasis : liverdominant disease 5 . Stage BCLC A , B , C 6 . ChildPugh A , ChildPugh B 7 point ( patient receive anticoagulant therapy : ChildPugh score 5 point ; INR category regard calculation ChildPugh score ) 7 . Willing comply study procedures 8 . Has voluntarily give write informed consent Exclusion Criteria 1 . If female , pregnant breast feeding ( female childbearing potential must use adequate contraception must negative pregnancy test perform within 7 day prior inclusion study ) 2 . If male , use adequate birth control measure 3 . One following : Hemoglobin &lt; 10g/dL , WBC &lt; 2,500 cells/mm3 , ANC &lt; 1,500 cells/mm3 , platelet &lt; 50,000/mm3 , ECOG performance status &gt; 2 4 . Life expectancy &lt; 16 week medically unstable 5 . Extrahepatic metastasis ( except metastasis bone , lymph node , adrenal gland constitute exclusion criterion ) , , see Additional Criteria Local Ablation Group , ( Section 4.2 study protocol ) 6 . Patients know GFR &lt; 30 mL/min/1.73m2 7 . PTINR/PTT &gt; 1.5 time upper limit normal ( patient anticoagulation therapy allow participate provide prior evidence exists underlie abnormality anticoagulation ) 8 . Uncontrolled infection time microtherapy 9 . ChildPugh score &gt; 7 point ; patient receive anticoagulant therapy : ChildPugh score &gt; 5 point ( INR category regard calculation ChildPugh score ) 10 . Uncontrolled ascites 11 . Tumor load whole liver &gt; 70 % 12 . Contraindications study medication accord product labeling procedure ( sorafenib , Primovist® , xray contrast agent , SIRSpheres® , RFA , MWA , MRI , CT ) incl . contraindication transarterial interventional procedure ( e.g. , allergy xray contrast agent , uncontrolled hyperthyroidism ) 13 . Prior resection papilla Vater ( e.g. , Whipple procedure ) bile duct stent across papilla 14 . Significant cardiovascular disease ; e.g. , myocardial infarction within 6 month inclusion , chronic heart failure ( New York Heart Association class III IV ) , unstable coronary artery disease 15 . Uncontrolled hypertension 16 . Thrombotic embolic event include transient ischemic attack within past 6 month ( tumorrelated portal vein thrombosis allow palliative part trial ) . 17 . History GI bleed within 30 day inclusion study 18 . History esophageal varix bleed control effective therapy and/or therapy prevent bleed recurrence 19 . Previous malignancy carcinoma situ skin cervix uterus within 5 year prior inclusion 20 . History organ transplant ( include prior liver transplantation ) 21 . HIV , congenital immune defect , immunosuppressive therapy autoimmune disease ( rheumatoid arthritis ) inflammatory bowel disease 22 . Mental condition render subject incapable understand nature , scope , consequence trial 23 . Close affiliation investigational site ; e.g . firstdegree relative investigator 24 . Participating another therapeutic clinical trial complete study participation another therapeutic clinical trial within 30 day enrolment trial 25 . Having previously enrol clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Liver</keyword>
	<keyword>HCC</keyword>
</DOC>